EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics (Malta) Limited

View source ↗

Summary

Zefylti (filgrastim) has been authorised by EMA for use in neutropenia, hematopoietic stem cell transplantation, and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation
• Neutropenia

Drugs mentioned

• Zefylti (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer. MAH: CuraTeQ Biologics (Malta) Limited. Decision date: 12/06/2026